Capital World Investors
INDV icon

Capital World Investors’s Indivior Pharmaceuticals INDV Stock Holding History

Capital World Investors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,284,920
Closed -$27.8M – 516
2023
Q3 		$27.8M Hold
1,284,920
– – 0.01% 421
2023
Q2 		$29.8M Buy
+1,284,920
New +$29.5M 0.01% 409

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Capital World Investors's INDV Position: Q4 2023 in Review

Capital World Investors sold out of Indivior Pharmaceuticals (INDV) in Q4 2023, closing a stake of 1,284,920 shares — an estimated $27.8M sold.

Capital World Investors first reported a position in INDV in Q2 2023 and held it in 2 quarters. The position peaked at $29.8M in Q2 2023. 76 funds tracked by Wall St. Rank hold INDV as of Q4 2023.

  • Capital World Investors reported no remaining Indivior Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Capital World Investors sold 1,284,920 Indivior Pharmaceuticals shares in Q4 2023, an estimated $27.8M.
  • Capital World Investors first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Capital World Investors's Indivior Pharmaceuticals position peaked at $29.8M in Q2 2023.
  • 76 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2023.

Based on Capital World Investors's 13F filing for Q4 2023, filed 13 Feb 2024.